DOI:
10.1055/s-00034914
Osteologie
LinksClose Window
References
Langdahl BL, Libanati C, Crittenden DB. et al.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in
postmenopausal women with osteoporosis transitioning from oral bisphosphonate
therapy: a randomised, open-label, phase 3 trial.
Lancet 2017;
390 (10102): 1585-1594
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.